Drug – bio-affecting and body treating compositions – Lymphokine – Interferon
Reexamination Certificate
2005-05-27
2010-06-08
Landsman, Robert (Department: 1647)
Drug, bio-affecting and body treating compositions
Lymphokine
Interferon
Reexamination Certificate
active
07731948
ABSTRACT:
A stabilized HSA-free liquid pharmaceutical composition is described, which comprises an interferon (IFN), wherein said formulation is a solution that comprises a buffer, an amino acid and an antioxidant. Preferably, the interferon is human recombinant IFN-beta.
REFERENCES:
patent: 4469228 (1984-09-01), Zupon et al.
patent: 4588585 (1986-05-01), Mark et al.
patent: 4695623 (1987-09-01), Stabinsky
patent: 4737462 (1988-04-01), Mark et al.
patent: 4879111 (1989-11-01), Chong
patent: 4897471 (1990-01-01), Stabinsky
patent: 4904584 (1990-02-01), Shaw
patent: 4959314 (1990-09-01), Mark et al.
patent: 4965195 (1990-10-01), Namen et al.
patent: 5017691 (1991-05-01), Lee et al.
patent: 5116943 (1992-05-01), Koths et al.
patent: 5541293 (1996-07-01), Stabinsky
patent: 5762923 (1998-06-01), Gross et al.
patent: 5858001 (1999-01-01), Tsals et al.
patent: 6013253 (2000-01-01), Martin et al.
patent: 6130200 (2000-10-01), Brodbeck et al.
patent: 6531122 (2003-03-01), Pedersen et al.
patent: 6569420 (2003-05-01), Chen et al.
patent: 6852314 (2005-02-01), Samaritani et al.
patent: 6923956 (2005-08-01), Tschope et al.
patent: 2002/0172661 (2002-11-01), Shirley et al.
patent: 2003/0138491 (2003-07-01), Tracy et al.
patent: 2007/0059285 (2007-03-01), Samaritani et al.
patent: 2007/0092487 (2007-04-01), Samaritani et al.
patent: 2007/0248674 (2007-10-01), Del Curto et al.
patent: 0098110 (1984-01-01), None
patent: 0177153 (1986-04-01), None
patent: 0509968 (1992-10-01), None
patent: 736303 (1996-10-01), None
patent: 1224940 (1998-09-01), None
patent: 1250932 (2000-05-01), None
patent: WO 95/31213 (1995-11-01), None
patent: WO 99/55377 (1999-11-01), None
patent: WO 00/24374 (2000-05-01), None
patent: WO 01/03737 (2001-01-01), None
patent: WO 01/58474 (2001-08-01), None
patent: WO 02/03472 (2002-01-01), None
patent: WO 02/09766 (2002-02-01), None
patent: WO 02/051386 (2002-07-01), None
patent: WO 03/066585 (2003-08-01), None
patent: WO 2004/002404 (2004-01-01), None
patent: WO 2005/110466 (2005-11-01), None
Cook, S. D. “Advancing Treatment with Interferon beta-1b (Betaferone®/Betaseron®) in the Next Decade”,J. Neurol., 2003, pp. IV/15-IV/20, vol. 25, Suppl. 4.
Derynck, R. et al. “Isolation and Structure of a Human Fibroblast Interferon Gene”,Nature, Jun. 19, 1980, pp. 542-547, vol. 285.
Rubinstein, S. et al. “Convenient Assay for Interferons”,Journal of Virology, Feb. 1981, pp. 755-758, vol. 37, No. 2.
Familletti, P. C. et al. “A Convenient and Rapid Cytopathic Effect Inhibition Assay for Interferon”,Methods in Enzymology, 1981, pp. 387-394, vol. 78.
Shepard, H. M. et al. “A Single Amino Acid Change in IFN-β1Abolishes its Antiviral Activity”,Nature, Dec. 10, 1981, pp. 563-565, vol. 294.
Mark, D. F. et al. “Site-Specific Mutagenesis of the Human Fibroblast Interferon Gene”,Proc. Natl. Acad. Sci., Sep. 1984, pp. 5662-5666, vol. 81.
Pestka, S. “Interferon Standards and General Abbreviations”,Methods in Enzymology, 1986, pp. 14-23, vol. 119.
Lam, X. M. et al. “The Effect of Benzyl Alcohol on Recombinant Human Interferon-γ”,Pharmaceutical Research, 1997, pp. 725-729, vol. 14, No. 6.
Schuck, P. “Size-Distribution Analysis of Macromolecules by Sedimentation Velocity Ultracentrifugation and Lamm Equation Modeling”,Biophysical Journal, Mar. 2000, pp. 1606-1619, vol. 78.
Wang, W. “Instability, Stabilization, and Formulation of Liquid Protein Pharmaceuticals”,International Journal of Pharmaceutics, 1999, pp. 129-188, vol. 185.
Wang, Y.-C. J. et al. “Parenteral Formulations of Proteins and Peptides: Stability and Stabilizers”,Journal of Parenteral Science&Technology, 1988, pp. S4-S26, vol. 42.
Bromberg, L. E. et al. “Temperature-responsive Gels and Thermogelling Polymer Matrices for Protein and Peptide Delivery”,Advanced Drug Delivery Reviews, 1998, pp. 197-221, vol. 31.
Chen-Chow, P.-C. et al. “In Vitro Release of Lidocaine from Pluronic F-127 Gels”,International Journal of Pharmaceutics, 1981, pp. 89-99, vol. 8.
Gander, B. et al. “Crosslinked Poloxamers as a Versatile Monolithic Drug Delivery System”,Drug Devel. And Indust. Pharmacy, 1986, pp. 1613-1623, vol. 12, Nos. 11-13.
Guzmán, M. et al. “Polyoxyethylene-polyoxypropylene Block Copolymer Gels as Sustained Release Vehicles for Subcutaneous Drug Administration”,International Journal of Pharmaceutics, 1992, pp. 119-127, vol. 80.
Johnston, T. P. et al. “Sustained Delivery of Interleukin-2 from a Poloxamer 407 Gel Matrix Following Intraperitoneal Injection in Mice”,Pharmaceutical Research, 1992, pp. 425-434, vol. 9, No. 3.
Katakam, M. et al. “Controlled Release of Human Growth Hormone in Rats Following Parenteral Administration of Poloxamer Gels”,Journal of Controlled Release, 1997, pp. 21-26, vol. 49.
Miyazaki, S. et al. “Pluronic F-127 Gels as a Novel Vehicle for Rectal Administration of Indomethacin”,Chem. Pharm. Bull., 1986, pp. 1801-1808, vol. 34, No. 4.
Schmolka, I. R. “A Review of Block Polymer Surfactants”,Journal of the American Oil Chemists' Society, Mar. 1977, pp. 110-116, vol. 54.
Stewart, W. E. et al. “Interferon Nomenclature”,J. Interferon Res., 1980, pp. vi-vii, vol. 1.
Stratton, L. P. et al. “Drug Delivery Matrix Containing Native Protein Precipitates Suspended in a Poloxamer Gel”,Journal of Pharmaceutical Sciences, Sep. 1997, pp. 1006-1010, vol. 86, No. 9.
Database WPI, Section Ch, Week 200406, Derwent Publicatons, Ltd., AN 2004-056676, XP-002301962 “Formulation for Injection of Interferon, Contains Interferon-alpha and Polyoxyethylene Polyoxypropylene Glycol”, Dec. 3, 2003, 1 page.
Prisms Study Group “Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis”The Lancet, Nov. 7, 1998, pp. 1498-1504, vol. 352.
Clegg, A. et al. “Immunomodulatory drugs for multiple sclerosis: a systematic review of clinical and cost effectiveness”Exp. Opin. Pharmacother., 2001, pp. 623-639, vol. 2, No. 4.
Hultgren, C. et al. “The antiviral compound ribavirin modulates the T helper (Th)1/Th2 subset balance in hepatitis B and C virus-specific immune responses”Journal of General Virology, 1998, pp. 2381-2391, vol. 79.
McCormick, J. B. et al. “Lassa Fever effective therapy with ribavirin”The New England Journal of Medicine, Jan. 2, 1986, pp. 20-26, vol. 314, No. 1.
Office Action dated Apr. 2, 2009 in U.S. Appl. No. 10/554,602.
Office Action dated Mar. 23, 2009 in U.S. Appl. No. 11/596,599.
Polman, C.H. et al. “Drug Treatment of Multiple Sclerosis”BMJ, Aug. 19-26, 2000, pp. 490-494, vol. 321.
Del Rio Alessandra
Samaritani Fabrizio
Ares Trading S.A.
Landsman Robert
Saliwanchik Lloyd & Saliwanchik
LandOfFree
Stabilized interferon liquid formulations does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Stabilized interferon liquid formulations, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Stabilized interferon liquid formulations will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4249518